PMID- 31001342
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1687-966X (Print)
IS  - 1687-9678 (Electronic)
VI  - 2019
DP  - 2019
TI  - Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Inhibit 
      Endometrial Cancer Cell Proliferation and Migration through Delivery of Exogenous 
      miR-302a.
PG  - 8108576
LID - 10.1155/2019/8108576 [doi]
LID - 8108576
AB  - MicroRNAs (miRNAs) are potential therapeutic targets in endometrial cancer, but 
      the difficulties associated with their delivery to tumor target cells have 
      hampered their applications. Human umbilical cord mesenchymal stem cells 
      (hUCMSCs) have a well-recognized tumor-homing ability, emphasizing the capacity 
      of tumor-targeted delivery of extracellular vesicles. hUCMSCs release 
      extracellular vesicles rich in miRNAs, which play a vital role in intercellular 
      communication. The purpose of this study was to verify a potential tumor 
      suppressor microRNA, miR-302a, and engineered hUCMSC extracellular vesicles 
      enriched with miR-302a for therapy of endometrial cancer. Here, we observed that 
      miR-302a was significantly downregulated in endometrial cancer tissues when 
      compared with adjacent tissues. Overexpression of miR-302a in endometrial cancer 
      cells robustly suppressed cell proliferation and migration. Meanwhile, the 
      proliferation and migration were significantly inhibited in endometrial cancer 
      cells when cultured with miR-302a-loaded extracellular vesicles derived from 
      hUCMSCs. Importantly, our data showed that engineered extracellular vesicles rich 
      in miR-302 significantly inhibited the expression of cyclin D1 and suppressed AKT 
      signaling pathway in endometrial cancer cells. These results suggested that 
      exogenous miR-302a delivered by hUCMSC-derived extracellular vesicles has 
      exciting potential as an effective anticancer therapy.
FAU - Li, Xin
AU  - Li X
AD  - Department of Obstetrics and Gynecology, Third Affiliated Hospital of Jinzhou 
      Medical University, Jinzhou, Liaoning 121001, China.
FAU - Liu, Li Li
AU  - Liu LL
AD  - Department of Obstetrics and Gynecology, Dalian Maternity Hospital, Dalian 
      Obstetrics and Gynecology Hospital Affiliated to Dalian Medical University, 
      Dalian, Liaoning 116000, China.
FAU - Yao, Ju Lei
AU  - Yao JL
AD  - Clinical and Translational Research Center, Shanghai First Maternity and Infant 
      Hospital, Tongji University School of Medicine, Shanghai 200040, China.
FAU - Wang, Kai
AU  - Wang K
AUID- ORCID: 0000-0003-2298-4816
AD  - Clinical and Translational Research Center, Shanghai First Maternity and Infant 
      Hospital, Tongji University School of Medicine, Shanghai 200040, China.
FAU - Ai, Hao
AU  - Ai H
AUID- ORCID: 0000-0003-3278-1000
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital, Key 
      laboratory of Follicular Development and Reproductive Health of Liaoning 
      Province, Jinzhou Medical University, Jinzhou, Liaoning 121001, China.
LA  - eng
PT  - Journal Article
DEP - 20190314
PL  - United States
TA  - Stem Cells Int
JT  - Stem cells international
JID - 101535822
PMC - PMC6437733
EDAT- 2019/04/20 06:00
MHDA- 2019/04/20 06:01
PMCR- 2019/03/14
CRDT- 2019/04/20 06:00
PHST- 2018/08/29 00:00 [received]
PHST- 2018/10/30 00:00 [revised]
PHST- 2018/11/14 00:00 [accepted]
PHST- 2019/04/20 06:00 [entrez]
PHST- 2019/04/20 06:00 [pubmed]
PHST- 2019/04/20 06:01 [medline]
PHST- 2019/03/14 00:00 [pmc-release]
AID - 10.1155/2019/8108576 [doi]
PST - epublish
SO  - Stem Cells Int. 2019 Mar 14;2019:8108576. doi: 10.1155/2019/8108576. eCollection 
      2019.